A slow start to the year in health care is usually tempered by announcements that build up to investor conference season. However, early 2022’s plethora of negative announcements may continue biotech’s unloved status of 2021.

Efforts to map disease using big data computing and speed drug discovery are gathering pace, with Verily among a wave of life science-focused tech companies.

The neuroscience-focused firm plans a 2022 supplemental NDA for Ingrezza following success in the pivotal KINECT-HD study. The biotech needed an R&D success after recent stumbles.

Despite recent setbacks for Roche and Wave's respective antisense offerings, both those two firms and a number of other companies are trying a variety of approaches to find a treatment for Huntington's.